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Abstract: Bone metastases are a frequent and important source of morbidity in cancer
patients. Stereotactic body radiation therapy (SBRT) is an established treatment option for
local control and pain relief of bone metastases, and it is increasingly used as upfront
treatment, postoperative consolidation or salvage treatment after prior RT. However, hetero-
geneity of dose schedules described in literature represents a severe limitation in the
deﬁnition of the role of SBRT as a standard of care. No consensus is available on the use
of single versus multiple fraction SBRT for bone metastases. Advantages of single-fraction
SBRT include shorter overall duration of treatment, absence of inter-fraction uncertainty,
improved compliance, theoretical increased efﬁcacy, and lower costs. However, caution has
been advised due to reports of severe late toxicities, in particular, vertebral collapse fracture
(VCF). The aim of this paper is to review dose fractionation and indications for the manage-
ment of bone metastases using SBRT.
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Introduction
Metastatic bone involvement is a frequent occurrence in cancer patients. It is present
in approximately 15 to 70% of advanced stage cancer patients according to primary
tumor localization, with an estimated incidence of 100,000 cases per year only in the
United States.1,2 Refractory pain is found in 70% of patients with bone metastases.1
Uncontrolled bone metastases (BM) are an important source of morbidity in
cancer patients, resulting in pathologic fractures, hypercalcemia, and neurologic
impairment.3 Bone metastases-related complications, collectively deﬁned as
Skeletal-Related Events (SRE), represent a serious threat to well-being and quality
of life in cancer patients.4 Moreover, the socio-economic burden of this condition is
also of primary concern, since monthly treatment cost raised from €190 in asympto-
matic patients to €4672 in patients with SRE in a prospective multicentric cohort.5
Conventional radiotherapy (CRT), delivering a range of radiation doses between 8
Gy in 1 fraction to 30 Gy in 10 fractions, is a mainstay of BMmanagement, providing
prompt symptom palliation with a benign toxicity proﬁle, and resort to other surgical
or medical treatment modalities does not obviate the use of radiotherapy.6 However,
long-term results are often disappointing, showing complete pain response only in
24% of patients, with no particular beneﬁt of one dose schedule over the other.7 Lack
of symptom control may also lead to high retreatment rates, in particular following
single fraction radiotherapy, though no beneﬁt was found in over 40% of patients
regardless of initial response to treatment or dose schedule.8 Achievement of durable
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disease and symptom control is of particular interest, due to
constant improvement in survival among cancer patients,9
most notably in speciﬁc subsets such as oligometastatic
patients who experience extended survival compared to
polymetastatic patients.10 Stereotactic body radiation ther-
apy (SBRT), deﬁned as delivery of high dose per fraction in
a short treatment course, allows the administration of poten-
tially ablative radiation doses to the core of target metas-
tases with a steep dose gradient that minimizes radiation
exposure of neighboring critical organs. For these reasons,
SBRT is an established treatment option for bone metas-
tases as primary treatment, and, particularly in case of
spinal involvement, as postoperative consolidation or sal-
vage treatment after prior RT.6 In comparison with conven-
tional palliative radiotherapy, delivery of highly
biologically effective radiation doses with SBRTmay result
in improved tumor control and fast symptom palliation.11
Results from the exploratory trial IRON-1 favors 24 Gy
single-fraction SBRT over 30 Gy in 10 fractions three-
dimensional radiotherapy (3DRT) in terms of pain relief,11
and randomized phase III studies12,13 are ongoing to assess
superiority of SBRT over CRT in terms of tumor control,
palliation of symptoms, and quality of life. Of note, SBRT
could be of particular interest in oligometastatic patients,
who may draw further beneﬁt in survival and systemic
therapy-free survival from reduction of disease burden
with the use of locally ablative therapies:14 pathologic
assessment of operated tumor specimen after SBRT proved
the absence of residual viable tumor in over 80% of cases,
thus conﬁrming the reliability of instrumental assessment
and demonstrating that SBRT is an ablative procedure in the
majority of cases.15 However, heterogeneity of dose sche-
dules described in literature represents a severe limitation in
the deﬁnition of the role of SBRT as a standard of care.
Comparable to CRT, no consensus is available on the use of
single versus multiple fraction SBRT for bone metastases.
Theoretical advantages of single-fraction radiotherapy over
multifractionated SBRT include shorter overall duration of
treatment, absence of inter-fraction uncertainty, improved
compliance, and lower costs.16 However, while historical
series mainly reported promising results following single
fraction irradiation, late occurrence of severe toxicities
(particularly in spinal treatment) motivated an increasingly
widespread use of multi-fractionated schedules in an
attempt to dampen toxicity. It is unclear whether fractiona-
tion may inﬂuence clinical outcome of patients treated with
SBRTwith regard to time to symptom palliation, duration of
pain control, need for a second radiotherapy course, and risk
of treatment-induced toxicities. This has important implica-
tions in clinical practice, since appropriate choice of treat-
ment schedule should be warranted in function of clinical
presentation of patients eligible for SBRT. The aim of this
paper is to review dose fractionations and indications for the
management of bone metastases using SBRT. A PubMed
search was performed on March 7th, 2019 using the terms
‹‹‹(stereotactic OR SBRTOR radiosurgery) AND (bone OR
spinal OR spine OR vertebral OR osseous) AND metas-
tases››, resulting in the identiﬁcation of 767 records.
Screening for appropriateness was carried out by 2 inde-
pendent author teams (ML/ID, DG/LL) in order to identify
relevant papers. For the purpose of this study, reviews, dose
planning studies or case reports were excluded, and articles
focusing on unrelated topics (including re-irradiation fol-
lowing prior conformal/stereotactic radiotherapy, post-sur-
gery consolidation radiotherapy, miscellaneous sites
including extraosseous localizations) were, likewise,
removed. In case of disagreement, a ﬁnal decision was
formulated with a third author (JJN). Full-text papers
assessed for eligibility and included for review are listed
in Tables 1 and 2.
Spinal Metastases
General Considerations
Axial skeleton is the most common site of secondary
localization, accounting for 40% of metastatic bone sites.17
Use of SBRT in the management of painful spinal metas-
tases was tested as early as the mid-1990s.18 SBRT was
initially intended as a single 8-Gy boost to the gross tumor
volume following conventional palliative radiotherapy, in
order to maximize dose to the tumor while respecting dose
constraints to the spinal cord: this resulted in promising
rates of pain palliation with no additional acute toxicity.19
Upfront use of SBRT in previously non-irradiated lesions
was prospectively validated by Garg et al.20 Feasibility of
dose escalation to 16 Gy was conﬁrmed in the phase II
trial RTOG 0631.13 Interestingly, precise tumor targeting
did not result in increased rate of marginal failures: since
one of the major arguments against the use of SBRT was
the omission of the adjacent vertebral level, this ﬁnding
justiﬁed the treatment of the involved spine only as pre-
viously reported by Ryu et al,21 who reported a relapse
rate of <5% in the immediately adjacent vertebrae. This
was conﬁrmed by Leeman et al, who showed involvement
of the adjacent vertebra in 2% of cases.22 A subsequent,
large prospective cohort study23 investigated the clinical
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outcome of single-fraction (20–25 Gy) SBRT in 500 spinal
metastases from mixed primary tumors, conﬁrming excel-
lent pain control in symptomatic tumors (290/336, 86%)
and neurologic impairment relief (27/32, 84%) at a median
follow-up of 21 (3–53) months. Modern series of SBRT
shows promising rates of 1-year local control between 60
and 95% and 1-year symptom control in 43 to 90% of
patients (Table 1 and Figure 1). Irrespective of the use of
single or multifractionated SBRT, a dose-response rela-
tionship has been highlighted: superior local control was
found in sarcoma metastases receiving a BED > 48 Gy,24
while, in another report on spinal metastases of miscella-
neous histology, local failure rate did not exceed 2% in
patients receiving a dose of at least 23.56 Gy EQD2 to
95% of the Gross Tumor Volume.25 Similar considerations
also apply to symptom relief: in the study by Jahaveri et al,
renal cell carcinoma patients (RCC) treated with a fractio-
nated schedule delivering a BED > 85 Gy achieved faster
and more durable pain control26 than patients receiving
inferior cumulative doses.
Single Or Multifractionated Spine SBRT?
While dose escalation might prove beneﬁcial, careful atten-
tion has been paid to attain clinically active doses while
respecting healthy tissues' tolerance constraints. In particular,
use of single fraction SBRT, the historical treatment modal-
ity, has been questioned due to reported incidence of verteb-
ral collapse fracture (VCF) in up to 39% of cases after a
single dose of 24 Gy or higher,27 thus advocating for the use
of fractionated schedules in an attempt to reduce severe
adverse events while maintaining effective cumulative
dose. However, optimal fractionation schedule allowing
acceptable trade-off between efﬁcacy and safety is a matter
of debate. It has been speculated that radiobiological effects
of a single radiation dose >15-20Gy may involve additional
biological activity compared to lower fractionated dose,
including asmase/ceramide pathway-related endothelial
damage.28 Pathologic assessment of resected metastases,
preoperatively treated with a single 18 Gy fraction, showed
signiﬁcant onset of tumor necrosis and decrease in vessel
density within 24 hrs.29 This observation supports the
hypothesis that more pronounced tumoricidal action, as
well as osteoradionecrosis, may occur after single fraction
SBRT following microvascular damage: hence, theoretical
superior efﬁcacy of single-fraction SBRT and increased risk
of local adverse events may represent two sides of the same
coin. However, in clinical practice no formal evidence is
available.T
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On one hand, several papers comparing different
SBRT dose schedules suggest signiﬁcantly higher pain control
rates30 and local control rates31,32 for single-fraction SBRT
compared tomultiple fraction. Nevertheless, fractionated regi-
mens employed in these studies may not be as dose-intensive
as single fraction SBRT. For example, in the study by Ghia
et al,31 24 Gy in a single fraction proved superior to 27 Gy in 3
fractions and 30 Gy in 5 fractions in terms of local control in
spinal metastases from RCC: however, using an alpha/beta
ratio of 10, this translated into very different corresponding
BED of 81.6, 51.3, and 48 Gy, respectively. Hence, use of
single fraction was associated with a nearly 1.5–2 fold BED
increase as compared to multifractionated schedules, which
may possibly explain superior outcome in this group of
patients; of note, follow-up at 5 years did not show increased
toxicity in patients receiving single-fraction SBRT, and global
incidence of VCF was 14%.33 Interestingly, in the paper by
Heron et al,30 amedian single dose of 16Gy (corresponding to
a BED=41.6Gy), while providing faster pain relief, resulted in
inferior local control as compared to a median 23.8–25 Gy in
4–5 fractions (corresponding to BED 37.1–38.4). In a large
cohort by Bishop et al, local relapse was correlated to inade-
quate tumor coverage independently of the fractionation,
advising a GTV Dmin above 14 Gy in 1 fraction and 21 Gy
in 3 fractions.24 It should be eventually pointed out that,
among the previously cited studies, superior tumor control
of single fraction schedule was assessed in subsets of patients
affected by radio-resistant primary tumors such as sarcoma
and RCC,31,32 while a single fraction of 14–18 Gy was insuf-
ﬁcient to overcome radioresistance in hepatocellular carci-
noma compared to other histotypes:34 therefore, though
tantalizing, the hypothesis of superior activity of single-frac-
tion SBRT according to tumor histology cannot be deﬁnitely
ruled out.
Table 2 Selected Studies On The Use Of Stereotactic Radiotherapy For Bone Metastases, Reporting Data On VCF Incidence And
Predictors
Study Type VCF
(%)
Dose
(Gy)
N°
Fractions
Risk Factor
Ozdemir et al,49 2019 Retrospective 4 16-18 1 Male gender, no bisphosphonates use, high SINS
Kelley et al,44 2019 Retrospective 9.5 16-40 1 to 5 N/A
Ito et al,51 2018 Retrospective 11.9 24 2 N/A
Tseng et al,40 2018 Prospective,
phase II
13.8 24 2 Spinal misalignment, lytic metastasis, dose to 90% of the PTV
Yoo et al,34 2017 Retrospective 28.5 16-45 1 to 3 Pre-existing VCF, lytic metastasis
Boyce-Fappiano et al,38 2017 Retrospective 11.9 10-60 1 to 5 Pre-existing VCF, lytic metastasis
Chang et al,52 2017 Retrospective 6.7 16-
52.5
1 to 3 N/A
Sharma et al,100 2017 Retrospective 7 14-16 1 N/A
Hashmi et al,101 2016 Retrospective 4.5 18-24 1 to 3 N/A
Pichon et al,50 2016 Prospective,
phase I
2 27 3 NB use of concurrent zoledronate
Bernstein et al,84 2016 Prospective,
phase II
0 18-30 1 to 5 N/A
Jawad et al,41 2016 Retrospective 5.7 8-40 1 to 5 Pre-existing VCF, solitary metastasis, EQD2 prescription dose
>38.4 Gy
Germano et al,85 2016 Retrospective 21 10-18 1 Colorectal histology, pre-existing VCF, severe pain
Moussazadeh et al,102 2015 Retrospective 36.1 24 1 N/A
Thibault et al,42 2015 Retrospective 18 16-24 1 Dose per fraction, pre-existing VCF, spinal misalignment
Guckenberger et al,53 2014 Retrospective 7.7 8-60 1 to 20 N/A
Balagamwala et al,90 2013 Retrospective 14 8-16 1 N/A
Sahgal et al,27 2013 Retrospective 14 8-35 1 to 5 Dose per fraction, pre-existing VCF, lytic metastasis, spinal
misalignment
Cunha et al,36 2013 Retrospective 11 8-35 1 to 5 Spinal misalignment, lytic metastasis, NSCLC and HCC
primary, dose per fraction ≥20 Gy
Boehling et al,43 2012 Retrospective 20 18-30 1 to 5 Age > 55 years, preexisting fracture, and baseline pain
Abbreviations: VCF, vertebra collapse fracture; N/A, not available; NSCLC, non-small cell lung cancer; HCC, hepatocellular carcinoma; EQD2, equivalent dose in 2 Gys;
PTV, planning treatment volume; SINS, spinal instability score.
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On the other hand, dose per fraction to the vertebral
body has been correlated to VCF and, most interestingly,
the use of single fraction doses as high as ≥20 Gy have
been questioned as a major risk factor. Incidence of VCF
(de novo or progression of existing fracture) varies greatly
among different authors (Table 2), and may occur within 5
years from the treatment.35 Following reports by Sahgal
et al, showing dose per fraction ≥20 and as ≥24 as an
independent risk factor for VCF (HR: 4.9 and 5.2, respec-
tively), caution has been advised concerning the use of
single fraction SBRT for spinal metastases.36 Since SBRT
schedules are not dose-equivalent, it is unclear whether
VCF risk is strictly dependent on dose per fraction rather
than cumulative dose: Jawad et al reported higher VCF
incidence for a 2-Gy equivalent dose (EQD2) >38.4 Gy
(corresponding approximately to 17, 24, and 29 Gy in 1, 3
Figure 1 A 68 year old woman affected by metastatic breast cancer was referred for SBRTof a painful metastasis of the left transverse pedicle of the 8th thoracic vertebra.
Notes: (A) MRI view prior to SBRT. (B) 18FDG-PET view prior to SBRT. (C) Dose planning prior to administration of a single fraction of 18 Gy to the 80% isodose line
(color wash deep orange, light blue, yellow, gold, purple, red and olive corresponding respectively to 14, 15, 16, 17, 18, 19, 20 and 21 Gy), resulting in conformal dose
distribution sparing the spinal canal (light orange). (D) 18FDG-PET view 6 months after SBRT, showing stable mineralization of the treated area and metabolic complete
response. Acute toxicity consisted of G2 dysphagia due to proximity of the esophagus. No late toxicity was observed at 1 year, while complete pain control was obtained.
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and 5 fractions, respectively) independently of the use of a
single or multiple fraction.37 However, to avoid oversim-
pliﬁcation, it should be pointed out that VCF is a complex
entity, that may result from a certain number of predispos-
ing factors other than dose schedule. Lytic metastases
show higher risk of VCF,27,34,36,38 and automatic calcula-
tion of the lytic component volume has been tested to
predict the risk of VCF.39 Spinal misalignment has also
been frequently found in patients experiencing VCF,27,36,40
as well as pre-existing VCF.27,34,40–43 Put together, all
these factors may participate in global mechanical instabil-
ity of the vertebra, that is of particular concern since it has
been correlated both to VCF onset and to local failure:
interestingly, Kelley et al reported superior local control
after single-fraction SBRT with a median dose of 16 (16–
20) Gy as compared to hypofractionated SBRT.44
Mechanical instability of vertebra should be constantly
addressed in patients potentially eligible for SBRT in
order to select candidates for this option and predict the
risk of complications. Consensus statement led to the
development of the Spinal Instability Neoplastic Score
(SINS),45 encompassing both clinical and radiological
ﬁndings: a subset analysis from a prospective phase II
trial conﬁrmed the performance of SINS in predicting the
onset of VCF after spine SBRT, showing a 2 year-VCF
rate of 31.6% in patients with high (7–12) SINS score
compared to 7.1% in patients with low (<7) SINS score.46
Careful spinal instability assessment may guide the choice
to consider prophylactic surgical stabilization or cement
augmentation after SBRT, that has been successfully prac-
tised in CRT47 and prospectively evaluated in a phase II
trial.48 Besides mechanical instability, other predictors of
VCF have been analyzed. Concurrent or prior biphospho-
nate administration, in particular for a treatment interval of
at least 6 months, may prevent the onset of VCF:49 use of
prophylactic zoledronic acid injection before hypofractio-
nated SBRT has been tested in a phase I trial, reporting a
2% incidence of VCF.50 A protective effect of obesity27
and prior irradiation42 has also been suggested.
Apart from VCF, no other toxicity seems to be inﬂu-
enced by SBRT schedule and few data are available due to
low incidence of late complications. In particular, radiation
myelopathy is exceedingly rare, presenting in less than 1%
of cases in current literature:35,51–53 interestingly, only a
maximum point dose (Dmax) corresponding to a BED>
110 Gy to spinal cord or cauda equina was correlated to
neurologic impairment, independently of the dose per
fraction.35 Conversely, esophageal toxicity is a frequent
occurrence following chest SBRT and may be life-threa-
tening in a small but signiﬁcant fraction of patients,54
leading to fatal outcome in rare cases due to massive
bleeding or ﬁstula.55–57 Interestingly, multiple dose con-
straints have been proposed, showing signiﬁcant inconsis-
tencies among authors: for example, suggested Dmax
extrapolated from clinical studies for esophagus single-
fraction SBRT ranged between 15.4 and 22 Gy.55,56 It is
likely that other variables, including organ motion, indivi-
dual radiosensitivity, prior chemotherapy and iatrogenic
manipulation may inﬂuence the incidence of esophageal
toxicity.54
Spine SBRT In Oligometastatic Disease
Oligometastatic patients represent a subset of metastatic
patients with low disease burden (inferior or equal to 3–5
metastases) potentially suitable for focal treatment in order
to obtain control of the macroscopic site of disease and
theoretically prolong survival.58 Focusing on metastatic
spinal involvement, a recent prospective cohort conﬁrmed
a signiﬁcant survival advantage (+22% at 6 months) in
patients with oligometastatic versus polymetastatic (>5
lesions) involvement, regardless of treatment modalities.
SBRT has been widely applied in this setting in order to
maximize disease control and symptom relief.59 In all the
available experiences (Table 1), the authors report excel-
lent local control rates in oligometastatic patients with
spinal involvement treated by SBRT, translating to
62–67% of patients achieving durable systemic-progres-
sion free survival at 1-year with modest incidence of
severe adverse events.52,60 Interestingly, superior local
control was shown in oligometastatic patients receiving
hypofractionated (3 to 5 fractions) SBRT to spinal metas-
tases as compared to polymetastatic patients. This may be
explained by elicitation of background immune response
toward tumor cells, or by retention of a less aggressive
phenotype in oligometastases.61 Therefore, it could be
speculated that dose fractionation may be involved in the
modulation of the local effect of SBRT through interaction
with tumor-host synergy;62 however, use of heterogeneous
dose schedule in these limited experiences do not allow
further analysis. Hence, no data are available concerning
the optimal dose schedule in oligometastatic patients,
though longer expected survival implies a more stringent
trade-off between risk of late toxicity and need for durable
local control. In order to guide the choice of the clinician,
multiple prognostic tools integrating clinical variables
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(PRISM, NOMS) in a decision framework are currently
available.63-65
Extra-Spinal Bone Metastases
General Considerations
Use of SBRT in non-spinal bone metastases has been
inconsistently described. First, there is a scarcity of litera-
ture speciﬁcally addressing SBRT for extra-spinal disease,
since most studies report miscellaneous data from spinal
and non-spinal treatment: however, treatment efﬁcacy
seems comparable with 1-year LC and pain control rate
of 75–100% and 13–100% (Table 1). Secondly, studies
addressing extra-spinal bone SBRT frequently include het-
erogeneous bone location: hence, choice of cumulative
dose and schedule fractionation may be inﬂuenced to a
variable degree by dose tolerance of neighboring critical
structures as compared to spinal SBRT, where radiation
myelopathy is commonly accepted as the main dose-limit-
ing toxicity.
Consensual deﬁnition of target volume is still lacking in
extraspinal metastases delineation, as opposed to spinal
SBRTwhere a consensus statement has been reached follow-
ing reports on pattern of failure and integration of MRI.66 To
our knowledge, only a recent paper by Ito et al67 examined
pattern of failure in 17 coxal metastases treated with a hypo-
fractionated schedule (30–35 Gy in 5 fractions) on an MRI-
delineated Gross Treatment Volume (GTV) plus a 5–10 mm
expansion to a Clinical Treatment Volume, showing a 41%
marginal/out of ﬁeld relapse incidence occurring at an aver-
age 3.4 cm distance (range 1.5–5.5) from the closer edge of
the treated tumor: hence, use of a Clinical Target Volume
expansion has been questioned.
Finally, heterogeneity in the study end-points (symptom
relief or local control) may indirectly reﬂect use of different
criteria for patient selection, in particular with regard to the
decision to allocate patients to SBRT rather than convention-
ally fractionated radiotherapy: for example, SBRT irradiation
of oligometastatic or oligoprogressive non-symptomatic
metastasis may underlie a positive bias due to inclusion of
a population subset characterized by a more favorable out-
come. Interestingly, only a recent retrospective cohort by Yu
et al68 identiﬁed patients according to the treatment intent:
despite evident differences in overall survival, no difference
in local control was found between oligometastatic, oligo-
progressive, and polymetastatic patients treated at the domi-
nant site of progression, showing a 1-year LC rate of 75.7%.
It is noteworthy that local control rate differed according to
criteria for response assessment, resulting in a 11.1% discre-
pancy between MDA and RECIST criteria, and a more
speciﬁc correlation between local control rate according to
MDA and improved survival was found.
Single Or Multifractionated Bone SBRT?
Since most studies on extra-spinal SBRT delivered mis-
cellaneous dose regimens, dose fractionation has not been
speciﬁcally addressed in current literature either in regard
to tumor and pain control or expected toxicity.
Interestingly, use of single fraction SBRT (15–24 Gy)
varies between 1.869 and 52%70 in retrospective cohorts.
Underutilization of single fraction SBRT in this setting
may result from reluctance among praticians to prescribe
single-fraction CRT in particular in long-surviving
patients, following widespread opinion that single fraction
would expose to increased toxicity, inadequate efﬁcacy,
and higher retreatment rate. However, it is currently
accepted that single fraction radiotherapy yields the same
efﬁcacy as multiple fraction CRT even in patients with
favorable expected survival.71 Moreover, delivering higher
dose to the target may further improve the therapeutic ratio
of single fraction CRT.72 Most interestingly, a recent phase
II trial73 comparing single-fraction SBRT to multifraction
CRT, reported signiﬁcantly higher rates of pain response
both at early (2 weeks) and late (9 months) evaluation.
Interestingly, according to a recent study from our group,
no speciﬁc SBRT dose fractionation was correlated to pain
control, that was mostly inﬂuenced by patient-related fea-
tures identiﬁed with the use of validated tools such as the
ECS-CP.74 Concerning toxicity, severe adverse events cor-
related with bone irradiation included fracture and pain
ﬂare (deﬁned as acute onset or exacerbation of pain in
relation to radiotherapy).75 Cumulative incidence of pain
ﬂare ranging between 10 and 68%70,75,76 has been
reported, with single-fraction dose regimen76 and lack of
steroid pretreatment77 being the main predictors. In our
experience, pain ﬂare occurred following 34% of SBRT
treatments74 but no variable was associated with its onset.
Owen et al described the occurrence of pain ﬂare and
fractures in 10% and 2% of 7 cases with a median dose of
24 Gy in one fraction.70 Erler et al69 reported an overall
fracture incidence of 8.5%, signiﬁcantly affecting female
patients and lytic metastases: however single-fraction
SBRT accounted only for 1.8% of treatment.
Regarding the previously cited prospective trial, no
differences in toxicity were shown in particular concerning
Loi et al Dovepress
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bone fracture, occurring in 1.2% of patients in the single-
fraction SBRT arm.
Conclusion
Stereotactic Body Radiotherapy (SBRT) is established as a
safe and effective treatment option for metastatic bone dis-
ease, resulting in prompt pain relief and excellent disease
control with acceptable toxicity: its applications range from
upfront treatment of painful metastases to re-irradiation of
previously treated sites in proximity to dose-limiting
organs, and to extend disease remission in oligometastatic
patients. Despite extensive literature, no deﬁnitive conclu-
sion can be drawn on the superiority of one regimen over
another: in particular it is unclear whether the use of multi-
fractionated versus single fraction SBRT schedule might
ensure a better therapeutic ratio between disease control
and adverse event risk.
In spinal metastases, while satisfying clinical efﬁcacy is
found with doses as low as 12–16 Gy in a single fraction, a
dose-response relationship has been highlighted that may
favor single-fraction schedules (in particular in radioresistant
histotypes), possibly through theoretical exploitation of alter-
native radiobiological effects involving vascular apoptosis,
occurring at >10-15 Gy/fraction. However, the use of doses
per fraction ≥ 20 Gy may increase the risk of severe adverse
events such as vertebral collapse fracture, in particular in
high risk patients (extended lytic component, spinal misa-
lignment, prior fracture): caution is advised in the use of
single fractions, that may be of interest in patients with low
spinal instability (SINS) score and/or in combination with
vertebroplasty. Conversely, myelopathy is an infrequent
event that may occur at high total doses (BED> 110 Gy)
independently from fractionation scheme. In extra-spinal
bone SBRT, scarce data are available: however, a recent
prospective trial suggests that, despite relative underutiliza-
tion, single fraction SBRT may not be burdened by higher
toxicity rates and proved prospectively superior to multi-
fractionated CRT in terms of pain relief. Multiple rando-
mized trials (NCT02608866; NCT03028337) are currently
comparing single versus multifraction SBRT.
Disclosure
The authors report no conﬂicts of interest in this work.
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